{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T16:49:27Z","timestamp":1776962967280,"version":"3.51.4"},"reference-count":21,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal Fran\u00e7ais d'Ophtalmologie"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jfo.2026.104832","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T16:08:36Z","timestamp":1774368516000},"page":"104832","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Predictive factors for non-response to intravitreal bevacizumab in diabetic macular edema"],"prefix":"10.1016","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6192-9273","authenticated-orcid":false,"given":"B.","family":"El Achour","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Ben Abderrazek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6363-0809","authenticated-orcid":false,"given":"A.","family":"Zahaf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Jabri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Hmaied","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfo.2026.104832_bib0110","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0161-6420(95)31052-4","article-title":"The Wisconsin epidemiologic study of diabetic retinopathy XV","volume":"102","author":"Klein","year":"1995","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2026.104832_bib0115","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.2337\/db09-1216","article-title":"Effect of prior intensive therapy in type 1 diabetes on 10-year progression of retinopathy in the DCCT\/EDIC: comparison of adults and adolescents","volume":"59","author":"White","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.jfo.2026.104832_bib0120","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.ophtha.2015.03.024","article-title":"Diabetic macular edema: pathophysiology and novel therapeutic targets","volume":"122","author":"Das","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2026.104832_bib0125","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.ophtha.2010.02.031","article-title":"Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema","volume":"117","author":"Elman","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2026.104832_bib0130","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1001\/archophthalmol.2012.1107","article-title":"Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab","volume":"130","author":"Bressler","year":"2012","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jfo.2026.104832_bib0135","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.oret.2017.02.003","article-title":"Outcomes of diabetic macular edema patients by baseline hemoglobin A1c","volume":"1","author":"Singh","year":"2017","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.jfo.2026.104832_bib0140","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.ophtha.2015.02.036","article-title":"Predictors of functional and anatomic outcomes in patients with diabetic macular edema treated with ranibizumab","volume":"122","author":"Sophie","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2026.104832_bib0145","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1136\/bjophthalmol-2013-303168","article-title":"Injection frequency and response to bevacizumab monotherapy for diabetic macular oedema (BOLT Report 5)","volume":"97","author":"Sivaprasad","year":"2013","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jfo.2026.104832_bib0150","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1186\/s12886-020-01578-8","article-title":"Systemic and ocular diseases associated with the development of diabetic macular edema among Japanese patients with diabetes mellitus","volume":"20","author":"Kume","year":"2020","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.jfo.2026.104832_bib0155","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s40942-016-0047-6","article-title":"Risk factors for diabetic retinopathy: a case-control study","volume":"2","author":"Lima","year":"2016","journal-title":"Int J Retina Vitreous"},{"key":"10.1016\/j.jfo.2026.104832_bib0160","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1097\/IAE.0b013e31826b6763","article-title":"Visual outcome after intravitreal bevacizumab depends on the optical coherence tomographic patterns of patients with diffuse diabetic macular edema","volume":"33","author":"Shimura","year":"2013","journal-title":"Retina"},{"key":"10.1016\/j.jfo.2026.104832_bib0165","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00417-011-1774-x","article-title":"Association between photoreceptor integrity and visual outcome in diabetic macular edema","volume":"250","author":"Shin","year":"2012","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jfo.2026.104832_bib0170","doi-asserted-by":"crossref","first-page":"39161","DOI":"10.1038\/srep39161","article-title":"Restoration of foveal photoreceptors after intravitreal ranibizumab injections for diabetic macular edema","volume":"6","author":"Mori","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.jfo.2026.104832_bib0175","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/s41598-020-57509-6","article-title":"Incidence and treatment outcomes of secondary epiretinal membrane following intravitreal injection for diabetic macular edema","volume":"10","author":"Kang","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.jfo.2026.104832_bib0180","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/eye.2016.317","article-title":"The incidence and risk factors for the development of vitreomacular interface abnormality in diabetic macular edema treated with intravitreal injection of anti-VEGF","volume":"31","author":"Chang","year":"2017","journal-title":"Eye"},{"key":"10.1016\/j.jfo.2026.104832_bib0185","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1167\/tvst.6.2.7","article-title":"A quantitative approach to predict differential effects of anti-VEGF treatment on diffuse and focal leakage in patients with diabetic macular edema: a pilot study","volume":"6","author":"Allingham","year":"2017","journal-title":"Transl Vis Sci Technol"},{"key":"10.1016\/j.jfo.2026.104832_bib0190","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.jfo.2019.12.006","article-title":"Les switchs de traitement dans l\u2019\u0153d\u00e8me maculaire diab\u00e9tique\u00a0: revue de la litt\u00e9rature et algorithme de prise en charge","volume":"43","author":"Couturier","year":"2020","journal-title":"J Fr Ophtalmol"},{"key":"10.1016\/j.jfo.2026.104832_bib0195","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.1007\/s00417-024-06531-9","article-title":"Faricimab for neovascular age-related macular degeneration and diabetic macular edema: from preclinical studies to phase 3 outcomes","volume":"262","author":"Agostini","year":"2024","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jfo.2026.104832_bib0200","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.3390\/cells11213362","article-title":"Diabetic macular edema: current understanding, molecular mechanisms and therapeutic implications","volume":"11","author":"Zhang","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.jfo.2026.104832_bib0205","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ajo.2022.01.004","article-title":"KESTREL and KITE: 52-week results from two phase III pivotal trials of brolucizumab for diabetic macular edema","volume":"238","author":"Brown","year":"2022","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jfo.2026.104832_bib0210","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.ophtha.2019.03.023","article-title":"Simultaneous inhibition of angiopoietin-2 and vascular endothelial growth factor-a with faricimab in diabetic macular edema","volume":"126","author":"Sahni","year":"2019","journal-title":"Ophthalmology"}],"container-title":["Journal Fran\u00e7ais d'Ophtalmologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0181551226000586?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0181551226000586?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T16:21:28Z","timestamp":1776961288000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0181551226000586"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0181551226000586"],"URL":"https:\/\/doi.org\/10.1016\/j.jfo.2026.104832","relation":{},"ISSN":["0181-5512"],"issn-type":[{"value":"0181-5512","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictive factors for non-response to intravitreal bevacizumab in diabetic macular edema","name":"articletitle","label":"Article Title"},{"value":"Journal Fran\u00e7ais d'Ophtalmologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfo.2026.104832","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104832"}}